New nasal spray mumps vaccines enter human testing
NCT ID NCT06967181
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing two new mumps vaccines given as a nasal spray, called CVM150 and CVM26, in up to 60 healthy adults aged 18-29. The main goal is to check if they are safe and to see how well they trigger an immune response. Unlike traditional shots, these vaccines are sprayed into the nose, which could make vaccination easier and more acceptable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CVM150 and CVM26 intranasal mumps virus vaccines
- What this could lead to
- If successful, this could lead to a new, needle-free mumps vaccine that is easier to administer and may provide better protection.
- What could go wrong
- This is a very early Phase 1 trial with only 60 healthy adults, so safety and immune response are still unknown. The vaccines may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUMPS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229, United States
-
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
-
University Of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.